Posted on

Adagio Therapeutics’ upsized IPO prices in middle of range, valued company at more than $1.8 billion – MarketWatch


Adagio Therapeutics Inc.
is set to go public Friday, after the upsized initial public offering of the Massachusetts-based biopharmaceutical company focused on antibody-based solutions for infectious diseases priced overnight at $17 a share, in the middle of the expected range. The company raised $309.4 million as it sold 18.2 million shares, up from expectations it would sell 17.7 million shares. At the IPO price the company was valued at $1.84 billion. The company is going public at a time of strong investor interest in IPOs, as the Renaissance IPO ETF
has soared 16.4% over the past three months while the S&P 500

Read More